CA2082811C - Utilisation du 5,10-methylene-tetrahydrofolate comme modulateur d'un agent chimiotherapeutique - Google Patents

Utilisation du 5,10-methylene-tetrahydrofolate comme modulateur d'un agent chimiotherapeutique Download PDF

Info

Publication number: CA2082811C
Authority: CA; Canada
Prior art keywords: chzfh4; ch2fh4; tetrahydrofolate; fdump; composition
Prior art date: 1990-05-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002082811A

Other languages

English (en)

Other versions

CA2082811A1 (fr

Inventor

Colin P. Spears

Bengt G. Gustavsson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Southern California USC

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-05-11

Filing date

1991-05-13

Publication date

2004-11-16

1991-05-13 Application filed by Individual filed Critical Individual

1991-11-12 Publication of CA2082811A1 publication Critical patent/CA2082811A1/fr

2004-11-16 Application granted granted Critical

2004-11-16 Publication of CA2082811C publication Critical patent/CA2082811C/fr

2011-05-13 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

QYNUQALWYRSVHF-OLZOCXBDSA-N (6R)-5,10-methylenetetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C1)N)N1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-OLZOCXBDSA-N 0.000 title claims description 9
239000002246 antineoplastic agent Substances 0.000 title description 5
229940127089 cytotoxic agent Drugs 0.000 title description 3
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims abstract description 85
229960002949 fluorouracil Drugs 0.000 claims abstract description 83
239000000203 mixture Substances 0.000 claims abstract description 41
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 80
HFEKDTCAMMOLQP-RRKCRQDMSA-N 5-fluorodeoxyuridine monophosphate Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(F)=C1 HFEKDTCAMMOLQP-RRKCRQDMSA-N 0.000 claims description 41
239000005460 tetrahydrofolate Substances 0.000 claims description 24
MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 claims description 23
238000000034 method Methods 0.000 claims description 23
239000003814 drug Substances 0.000 claims description 15
ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims description 15
229940079593 drug Drugs 0.000 claims description 13
239000003795 chemical substances by application Substances 0.000 claims description 8
231100000419 toxicity Toxicity 0.000 claims description 8
230000001988 toxicity Effects 0.000 claims description 8
229960000961 floxuridine Drugs 0.000 claims description 7
230000002829 reductive effect Effects 0.000 claims description 7
230000004614 tumor growth Effects 0.000 claims description 7
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 6
GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 claims description 6
239000004052 folic acid antagonist Substances 0.000 claims description 6
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical group OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 6
229960000485 methotrexate Drugs 0.000 claims description 6
WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 claims description 6
229960001674 tegafur Drugs 0.000 claims description 6
125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 claims description 5
KOKTUHPFPWFELE-HCWSKCQFSA-N 1-[(2s,3r,4s,5r)-2-fluoro-3,4-dihydroxy-5-methyloxolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@@]1(F)N1C(=O)NC(=O)C=C1 KOKTUHPFPWFELE-HCWSKCQFSA-N 0.000 claims description 4
108010024636 Glutathione Proteins 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 4
NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 claims description 4
229960001099 trimetrexate Drugs 0.000 claims description 4
239000001272 nitrous oxide Substances 0.000 claims description 3
229960001730 nitrous oxide Drugs 0.000 claims description 3
230000000694 effects Effects 0.000 abstract description 23
150000001875 compounds Chemical class 0.000 abstract description 11
230000001225 therapeutic effect Effects 0.000 abstract description 8
-1 compound 5,10-methylene-tetrahydrofolate Chemical class 0.000 abstract description 4
230000005917 in vivo anti-tumor Effects 0.000 abstract description 3
108010022394 Threonine synthase Proteins 0.000 description 98
102000005497 Thymidylate Synthase Human genes 0.000 description 93
206010028980 Neoplasm Diseases 0.000 description 60
239000011672 folinic acid Substances 0.000 description 47
229960001691 leucovorin Drugs 0.000 description 47
VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 46
235000008191 folinic acid Nutrition 0.000 description 46
VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 46
230000005764 inhibitory process Effects 0.000 description 39
235000019152 folic acid Nutrition 0.000 description 38
239000011724 folic acid Substances 0.000 description 33
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 29
229940014144 folate Drugs 0.000 description 26
239000000243 solution Substances 0.000 description 23
201000011510 cancer Diseases 0.000 description 22
230000015572 biosynthetic process Effects 0.000 description 18
150000002224 folic acids Chemical class 0.000 description 18
238000003556 assay Methods 0.000 description 16
229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 13
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
102000004190 Enzymes Human genes 0.000 description 12
108090000790 Enzymes Proteins 0.000 description 12
210000001519 tissue Anatomy 0.000 description 11
238000001574 biopsy Methods 0.000 description 10
229910052799 carbon Inorganic materials 0.000 description 10
238000009472 formulation Methods 0.000 description 10
230000003834 intracellular effect Effects 0.000 description 10
TZBGSHAFWLGWBO-ABLWVSNPSA-N (2s)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pteridin-6-yl)methylamino]benzoyl]amino]-5-methoxy-5-oxopentanoic acid Chemical compound C1=CC(C(=O)N[C@@H](CCC(=O)OC)C(O)=O)=CC=C1NCC1NC(C(=O)NC(N)=N2)=C2NC1 TZBGSHAFWLGWBO-ABLWVSNPSA-N 0.000 description 9
239000000463 material Substances 0.000 description 9
239000000843 powder Substances 0.000 description 9
238000003786 synthesis reaction Methods 0.000 description 9
206010009944 Colon cancer Diseases 0.000 description 8
238000002955 isolation Methods 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
239000003381 stabilizer Substances 0.000 description 8
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 7
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 7
210000004027 cell Anatomy 0.000 description 7
GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 7
OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 7
238000010790 dilution Methods 0.000 description 7
239000012895 dilution Substances 0.000 description 7
229960000304 folic acid Drugs 0.000 description 7
230000007246 mechanism Effects 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
241000700159 Rattus Species 0.000 description 6
229940072107 ascorbate Drugs 0.000 description 6
235000010323 ascorbic acid Nutrition 0.000 description 6
239000011668 ascorbic acid Substances 0.000 description 6
JSRLJPSBLDHEIO-SHYZEUOFSA-N dUMP Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 JSRLJPSBLDHEIO-SHYZEUOFSA-N 0.000 description 6
238000001802 infusion Methods 0.000 description 6
230000001012 protector Effects 0.000 description 6
230000004044 response Effects 0.000 description 6
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical class N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 5
206010016880 Folate deficiency Diseases 0.000 description 5
244000199866 Lactobacillus casei Species 0.000 description 5
230000000259 anti-tumor effect Effects 0.000 description 5
208000029742 colonic neoplasm Diseases 0.000 description 5
102000004419 dihydrofolate reductase Human genes 0.000 description 5
BADXJIPKFRBFOT-UHFFFAOYSA-N dimedone Chemical compound CC1(C)CC(=O)CC(=O)C1 BADXJIPKFRBFOT-UHFFFAOYSA-N 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
239000000126 substance Substances 0.000 description 5
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 4
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
102100035353 Cyclin-dependent kinase 2-associated protein 1 Human genes 0.000 description 4
241000282414 Homo sapiens Species 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000000670 ligand binding assay Methods 0.000 description 4
230000003285 pharmacodynamic effect Effects 0.000 description 4
239000000758 substrate Substances 0.000 description 4
235000019156 vitamin B Nutrition 0.000 description 4
239000011720 vitamin B Substances 0.000 description 4
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
MSTNYGQPCMXVAQ-NEPJUHHUSA-N 6R-Tetrahydrofolic acid Chemical compound C([C@@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-NEPJUHHUSA-N 0.000 description 3
206010006187 Breast cancer Diseases 0.000 description 3
208000026310 Breast neoplasm Diseases 0.000 description 3
GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
241001529936 Murinae Species 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000003570 air Substances 0.000 description 3
229940024606 amino acid Drugs 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000003466 anti-cipated effect Effects 0.000 description 3
229910052786 argon Inorganic materials 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
230000009918 complex formation Effects 0.000 description 3
239000006071 cream Substances 0.000 description 3
238000010828 elution Methods 0.000 description 3
206010017758 gastric cancer Diseases 0.000 description 3
239000011521 glass Substances 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
238000002372 labelling Methods 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
230000002503 metabolic effect Effects 0.000 description 3
230000004060 metabolic process Effects 0.000 description 3
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 3
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
238000000159 protein binding assay Methods 0.000 description 3
238000000746 purification Methods 0.000 description 3
238000007142 ring opening reaction Methods 0.000 description 3
238000000926 separation method Methods 0.000 description 3
229940113082 thymine Drugs 0.000 description 3
230000003442 weekly effect Effects 0.000 description 3
MEANFMOQMXYMCT-OLZOCXBDSA-M (6R)-5,10-methenyltetrahydrofolate Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2[N+]1=C1)N)N1C1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 MEANFMOQMXYMCT-OLZOCXBDSA-M 0.000 description 2
VVIAGPKUTFNRDU-STQMWFEESA-N (6S)-5-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=O)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-STQMWFEESA-N 0.000 description 2
HNXQXTQTPAJEJL-UHFFFAOYSA-N 2-aminopteridin-4-ol Chemical compound C1=CN=C2NC(N)=NC(=O)C2=N1 HNXQXTQTPAJEJL-UHFFFAOYSA-N 0.000 description 2
WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical compound FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 description 2
241000237519 Bivalvia Species 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
208000001126 Keratosis Diseases 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
241001136616 Methone Species 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
206010038019 Rectal adenocarcinoma Diseases 0.000 description 2
208000009527 Refractory anemia Diseases 0.000 description 2
208000005718 Stomach Neoplasms Diseases 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
230000003432 anti-folate effect Effects 0.000 description 2
229940127074 antifolate Drugs 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
230000003078 antioxidant effect Effects 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
238000012937 correction Methods 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
GRWZHXKQBITJKP-UHFFFAOYSA-L dithionite(2-) Chemical compound [O-]S(=O)S([O-])=O GRWZHXKQBITJKP-UHFFFAOYSA-L 0.000 description 2
ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 2
229950005454 doxifluridine Drugs 0.000 description 2
238000000605 extraction Methods 0.000 description 2
150000005699 fluoropyrimidines Chemical class 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 2
229960003180 glutathione Drugs 0.000 description 2
230000012010 growth Effects 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000006872 improvement Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000037356 lipid metabolism Effects 0.000 description 2
208000014018 liver neoplasm Diseases 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
238000007069 methylation reaction Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
239000002547 new drug Substances 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
230000000803 paradoxical effect Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
201000001281 rectum adenocarcinoma Diseases 0.000 description 2
230000009467 reduction Effects 0.000 description 2
229960001153 serine Drugs 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
201000011549 stomach cancer Diseases 0.000 description 2
238000003860 storage Methods 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
231100000027 toxicology Toxicity 0.000 description 2
238000012546 transfer Methods 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
DMUOPRHPAOSLAO-PJKMHFRUSA-N 1-[(2s,4s,5r)-4-hydroxy-5-(hydroxymethyl)-2-(trifluoromethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@]1(C(F)(F)F)O[C@H](CO)[C@@H](O)C1 DMUOPRHPAOSLAO-PJKMHFRUSA-N 0.000 description 1
WTLKTXIHIHFSGU-UHFFFAOYSA-N 2-nitrosoguanidine Chemical compound NC(N)=NN=O WTLKTXIHIHFSGU-UHFFFAOYSA-N 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
206010002065 Anaemia megaloblastic Diseases 0.000 description 1
238000012935 Averaging Methods 0.000 description 1
208000000412 Avitaminosis Diseases 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
208000018240 Bone Marrow Failure disease Diseases 0.000 description 1
206010065553 Bone marrow failure Diseases 0.000 description 1
GFKCZHFKMGKIAQ-OLZOCXBDSA-N C([C@@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 Chemical compound C([C@@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 GFKCZHFKMGKIAQ-OLZOCXBDSA-N 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
208000009458 Carcinoma in Situ Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000002667 Glycine hydroxymethyltransferase Human genes 0.000 description 1
108010043428 Glycine hydroxymethyltransferase Proteins 0.000 description 1
206010019695 Hepatic neoplasm Diseases 0.000 description 1
206010023347 Keratoacanthoma Diseases 0.000 description 1
231100000349 LDLo Toxicity 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
208000000682 Megaloblastic Anemia Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
108010010685 Methenyltetrahydrofolate cyclohydrolase Proteins 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010035660 Pneumocystis Infections Diseases 0.000 description 1
108010020346 Polyglutamic Acid Proteins 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
230000006819 RNA synthesis Effects 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
206010047627 Vitamin deficiencies Diseases 0.000 description 1
XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
239000012080 ambient air Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000008238 biochemical pathway Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000013590 bulk material Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910021386 carbon form Inorganic materials 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
230000005465 channeling Effects 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
239000012829 chemotherapy agent Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000000112 colonic effect Effects 0.000 description 1
238000007398 colorimetric assay Methods 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
229940099302 efudex Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
239000000284 extract Substances 0.000 description 1
108010022790 formyl-methenyl-methylenetetrahydrofolate synthetase Proteins 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
208000010749 gastric carcinoma Diseases 0.000 description 1
239000003292 glue Substances 0.000 description 1
229940049906 glutamate Drugs 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 description 1
238000007871 hydride transfer reaction Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 description 1
235000007635 levomefolic acid Nutrition 0.000 description 1
239000011578 levomefolic acid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
206010025382 macrocytosis Diseases 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
231100001016 megaloblastic anemia Toxicity 0.000 description 1
230000011987 methylation Effects 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
231100000219 mutagenic Toxicity 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
235000018343 nutrient deficiency Nutrition 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
235000015497 potassium bicarbonate Nutrition 0.000 description 1
229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
239000011736 potassium bicarbonate Substances 0.000 description 1
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
239000012254 powdered material Substances 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000022558 protein metabolic process Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000004144 purine metabolism Effects 0.000 description 1
230000006825 purine synthesis Effects 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000006824 pyrimidine synthesis Effects 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
150000003246 quinazolines Chemical class 0.000 description 1
238000009790 rate-determining step (RDS) Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
208000020615 rectal carcinoma Diseases 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000005070 sampling Methods 0.000 description 1
FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 1
229960004617 sapropterin Drugs 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
241000894007 species Species 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
201000000498 stomach carcinoma Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
230000008427 tissue turnover Effects 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002082811A 1990-05-11 1991-05-13 Utilisation du 5,10-methylene-tetrahydrofolate comme modulateur d'un agent chimiotherapeutique Expired - Lifetime CA2082811C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US52171290A	1990-05-11	1990-05-11
US521,712		1990-05-11
PCT/US1991/003186 WO1991017660A1 (fr)	1990-05-11	1991-05-13	5,10-methylene-tetrahydrofolate comme modulateur d'un agent chimiotherapeutique

Publications (2)

Publication Number	Publication Date
CA2082811A1 CA2082811A1 (fr)	1991-11-12
CA2082811C true CA2082811C (fr)	2004-11-16

Family

ID=24077829

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002082811A Expired - Lifetime CA2082811C (fr)	1990-05-11	1991-05-13	Utilisation du 5,10-methylene-tetrahydrofolate comme modulateur d'un agent chimiotherapeutique

Country Status (3)

Country	Link
AU (1)	AU7953291A (fr)
CA (1)	CA2082811C (fr)
WO (1)	WO1991017660A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH684644A5 (de) *	1992-07-13	1994-11-15	Eprova Ag	5,10-Methylentetrahydrofolsäure-Cyclodextrin-Einschlussverbindungen.
US5719132A (en) *	1996-06-27	1998-02-17	Bristol-Myers Squibb Company	Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
CH693255A5 (de) *	1997-06-13	2003-05-15	Eprova Ag	Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
SE0303526D0 (sv) *	2003-12-22	2003-12-22	Biofol Ab	Chemotherapeutic agents
EP2617421A1 (fr) *	2012-01-20	2013-07-24	Isofol Medical AB	Tétrahydrofolates en combinaison avec les inhibiteurs EGFR dans l'utilisation pour le traitement du cancer

1991
- 1991-05-13 CA CA002082811A patent/CA2082811C/fr not_active Expired - Lifetime
- 1991-05-13 AU AU79532/91A patent/AU7953291A/en not_active Abandoned
- 1991-05-13 WO PCT/US1991/003186 patent/WO1991017660A1/fr not_active Ceased

Also Published As

Publication number	Publication date
AU7953291A (en)	1991-12-10
WO1991017660A1 (fr)	1991-11-28
CA2082811A1 (fr)	1991-11-12

Legal Events

Date	Code	Title	Description
1998-05-13	EEER	Examination request
2011-05-13	MKEX	Expiry

Publication	Publication Date	Title
Jackman et al.	1995	ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer
Bleyer	1977	Methotrexate: clinical pharmacology, current status and therapeutic guidelines
Moran	1989	Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase
Shirasaka et al.	1993	Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo
Spears et al.	1988	Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil
Zager et al.	1973	The effects of antibiotics and cancer chemotherapeutic agents on the cellular transport and antitumor activity of methotrexate in L1210 murine leukemia
US6046159A (en)	2000-04-04	Formulations and methods of reducing toxicity of antineoplastic agents
Peters et al.	1987	Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390)
Jacobs et al.	1975	Stoichiometric inhibition of mammalian dihydrofolate reductase by the γ-glutamyl metabolite of methotrexate, 4-amino-4-deoxy-N10-methylpteroylglutamyl-γ-glutamate
Jackman et al.	1996	TomudexTM (ZD1694): from concept to care, a programme in rational drug discovery
Black et al.	1990	Antineoplastic drugs in 1990: a review (part I)
US5376658A (en)	1994-12-27	5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent
US9180128B2 (en)	2015-11-10	Stable pharmaceutical compositions of 5,10-methylene tetrahydrofolate
Fernandes et al.	1983	Biochemical and antitumor effects of 5, 8-dideazaisopteroylglutamate, a unique quinazoline inhibitor of thymidylate synthase
Natsumeda et al.	1985	Purine enzymology of human colon carcinomas
CA2082811C (fr)	2004-11-16	Utilisation du 5,10-methylene-tetrahydrofolate comme modulateur d'un agent chimiotherapeutique
McGuire et al.	1986	Folylpolyglutamate synthetase inhibition and cytotoxic effects of methotrexate analogs containing 2, ω-diaminoalkanoic acids
Philips et al.	1973	Uptake of methotrexate, aminopterin, and methasquin and inhibition of dihydrofolate reductase and of DNA synthesis in mouse small intestine
Voytek et al.	1977	Comparative studies of the cytostatic action and metabolism of 5-azacytidine and 5, 6-dihydro-5-azacytidine
Sigel et al.	1987	Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase
Rustum	1990	Biochemical rationale for the 5-fluorouracil leucovorin combination and update of clinical experience
Chu et al.	1996	Mechanisms of clinical resistance to 5-fluorouracil chemotherapy
Judson	1997	'Tomudex'(raltitrexed) development: preclinical, phase I and II studies
Spears et al.	1989	Deoxyuridylate effects on thymidylate synthase-5-fluorodeoxyuridylate-folate ternary complex formation
Kovoor et al.	2009	Is levoleucovorin an alternative to racemic leucovorin? A literature review